Home / Editorial Board / Jonathan Snipes, MD
Written by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Jonathan Snipes, MD

Medical Reviewer

Jonathan Snipes, MD is the physician medical reviewer for Tirzepatide Watchdog. He reviews clinical guides, safety content and any page making medication-specific claims, checking mechanism, indication, contraindication and risk language against FDA labeling and primary clinical literature. His NPI record (1821250077) is listed in the CMS National Plan and Provider Enumeration System registry.

Credentials & verification

Role
Medical Reviewer
NPI
1821250077 — verified in the CMS National Plan & Provider Enumeration System registry
Review scope
Physician-level medical review: medication guides, safety pages, dosing context, regulatory status.
Verification
NPI record checked against the CMS NPPES registry.

Conflict disclosure

Jonathan Snipes, MD is not compensated based on any reviewed provider's sales. Where a page involves NexLife, our ownership relationship is disclosed on that page, and the NexLife score is signed off by an unaffiliated reviewer. See our conflicts-of-interest policy.

SURMOUNT-1 — mean body-weight reduction by tirzepatide dose, 72 weeks
06111723Placebo3%Tirzepatide 5mg15%Tirzepatide 10mg20%Tirzepatide 15mg21%

Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.

Role and scope

Dr. Jonathan Snipes, MD — Medical Reviewer. NPI 1821250077, verified against the CMS National Plan and Provider Enumeration System.

Dr. Snipes reviews medical claims for accuracy, and specifically for the boundary between what a trial demonstrated and what it did not — the distinction between an FDA-approved subcutaneous injection and a compounded preparation, between a randomised trial and an observational study, and between a trial mean and an individual promise.

What we publish, and what we deliberately do not

This profile contains only information that has been confirmed to us. We publish the name, the credential, the editorial role, the scope of review, and — where it exists — an NPI that we have checked against the CMS registry.

We do not publish specialty, board certification, state licence, hospital affiliation, university affiliation, awards, professional memberships, or biography unless each has been separately verified. Padding a reviewer profile with unverified professional detail is one of the commonest ways a health site manufactures authority, and we would rather this page look thin than look impressive on facts we cannot stand behind.

Conflict disclosure

Publisher relationshipsMaterial relationship disclosure. Tirzepatide Watchdog is published by US Peptides Partners LLC. The publisher and certain principals have financial relationships with several of the providers listed on this site, and we may receive compensation when readers use certain links.

Relationships the publisher has confirmed to date: NexLife (financial interest). Where a provider is not named here, that is because the publisher has not confirmed a relationship — it is not a statement that we have verified its absence. We would rather show you that gap than imply an independence we have not checked.

Compensation does not increase the price you pay, and does not permit any provider to purchase a verification status, alter a documented fact, remove a material limitation, change a ranking, or bypass our published editorial and medical-review standards.

No reviewer on this site is compensated based on any provider’s sales, and no employee, executive or medical director of any reviewed provider writes, reviews, scores or approves that provider’s page. NexLife’s medical director, Dr. Adam Kennah, has no role in our editorial process. We name him on the NexLife review because he is a fact about NexLife — not because he has anything to do with our independence.